Based on this prediction model, the low-risk group, consisting of patients with <4 tumors, tumor size ≤10 cm, absence of tumor rupture, compensated liver function, and AFP <400 ng/mL, could benefit most from TACE. This evidence concerns the gene AFP and neoplasm.